<DOC>
	<DOCNO>NCT00783536</DOCNO>
	<brief_summary>This randomize , open label , active-comparator , parallel design , outpatient , multicenter study conduct Mexico . Subjects early active Rheumatoid Arthritis ( RA ) receive treatment Disease-modifying antirheumatic drug ( DMARD ) previous 6 month eligible study . Study subject randomize one two treatment group receive either etanercept + methotrexate standard non-biologic DMARD therapy .</brief_summary>
	<brief_title>A Multicenter Study Compare Efficacy Safety Combination Etanercept Methotrexate Treatment Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1 . Male female subject age 18 year old 2 . Diagnosis RA 3 . Disease duration ≥ 6 month ≤ 2 year 4 . Active disease time randomization 5 . Negative serum pregnancy test screen female childbearing potential . 6 . Women childbearing potential participating study must use medically acceptable form contraception . 7 . Sexually active male must agree use medically accept form contraception study . If partner use acceptable form contraception , criterion applicable . 8 . Subject capable understanding signing informed consent form 9 . Subject able willing selfinject study drug designee 10 . Subject able willing take oral medication 11 . Subject able store injectable test article 2° C 8° C 12 . Demonstrates negative tuberculosis screen test determine chest Exculsion Criteria : 1 . Subject receive previous treatment ETN tumor necrosis factor ( TNF ) antagonist 2 . Subject receive following DMARDs : methotrexate , leflunomide , hydroxychloroquine , chloroquine , cyclosporine , sulphasalazine , azathioprine , Dpenicillamine , cyclophosphamide within 6 month screen visit rheumatologist 3 . Subject receive investigational drug within 3 month screen visit rheumatologist 4 . Subject receive biologic agent past 5 . Subject receive live ( attenuate ) vaccine within 4 week screen visit rheumatologist 6 . Subject receive intraarticular corticosteroid injection within 4 week screen visit rheumatologist 7 . Subject receive bolus intramuscular/intravenous treatment corticosteroid ( &gt; 20 mg prednisone equivalent ) within 4 week screen visit rheumatologist 8 . Subject take &gt; 10 mg/day prednisone equivalent within 4 week screen visit rheumatologist 9 . A history active presence follow item prevent enrollment : Significant concurrent medical disease include cancer history cancer Renal disease ( creatinine level &gt; 175 ? mol/L ) History drug abuse psychiatric disease would interfere subject 's ability comply requirement protocol . History alcohol abuse would interfere subject 's ability comply requirement protocol . History know liver cirrhosis , fibrosis , fatty liver History viral hepatitis within 1 year screen 10 . Active presence follow also prevent enrollment Subject significant active infection underlying disease could predispose subject infection accord investigator criteria Demonstrates liver function abnormality clinical significant hepatic enzyme result ( twice upper limit normal ) . Subject leucopoenia ( white blood cell &lt; 3500 x 106/L ) Subject thrombocytopenia ( platelet &lt; 125 x 109/L ) Subject hemoglobin level &lt; 85 g/L Subject schedule elective major surgery within first year study participation Pregnant lactate woman . Positive TB PPD abnormal chest ray 11 . Subject history confirm blood dyscrasias12 . Subject condition judge physician cause study detrimental subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>An randomize , open label , multicenter study compare ef</keyword>
</DOC>